
Biocon has received US Food and Drug Administration approval for Pebrilzo (pertuzumab-qcay), a biosimilar to Genentech's Perjeta used in HER2-positive breast cancer. It is the company's fifth oncology biosimilar to clear the US FDA, adding to its portfolio of Ogivri, Jobevne, Fulphila and Aukelso. The drug is indicated with trastuzumab and chemotherapy for early-stage and metastatic disease.

Biocon has entered a global settlement with Genentech securing the earliest licensed US launch date in the third quarter of calendar year 2028. In September, the European Medicines Agency's expert committee recommended marketing approval for Pebrilzo in Europe across multiple disease stages. The label carries warnings about cardiac risk and fetal harm, requiring regular monitoring and contraception during treatment.
CEO Shreehas Tambe said the approval strengthens the anti-cancer portfolio and advances the company's commitment to affordable biologic medicines. Biocon's pipeline includes biosimilars to trastuzumab/hyaluronidase, nivolumab and pembrolizumab. Shares were trading 0.15 percent lower at ₹363.50 on Monday.
Both Business Standard and CNBC-TV18 report identically on the regulatory win, Biocon's fifth biosimilar, and the licence deal setting a Q3 2028 US entry. Where they differ is in emphasis: Business Standard leads with the approval and its pipeline significance, and quotes CEO Shreehas Tambe on patient financial strain. CNBC-TV18 leads with the stock move, adds share price data, and includes safety warnings from the label. The overlapping core facts mean the coverage is uniform on the substance. The only open point is whether the stock movement reflects market disappointment over the 2028 launch window, which CNBC-TV18 hints at with the day's slight fall of 0.15 percent at ₹363.50.
Coverage: 2 sources, 2 neutral
Sources (2): business-standard.com (neutral report), cnbctv18.com (neutral report)
This brief was synthesised by AI from the 2 sources linked above, so one read covers every framing they carry. Methodology and corrections.